IS7633A - Notkun á rauðkornavaka - Google Patents
Notkun á rauðkornavakaInfo
- Publication number
- IS7633A IS7633A IS7633A IS7633A IS7633A IS 7633 A IS7633 A IS 7633A IS 7633 A IS7633 A IS 7633A IS 7633 A IS7633 A IS 7633A IS 7633 A IS7633 A IS 7633A
- Authority
- IS
- Iceland
- Prior art keywords
- epo
- tissue
- endothelial
- derivatives
- stimulating
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 4
- 210000000056 organ Anatomy 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000003511 endothelial effect Effects 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 abstract 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 102100035194 Placenta growth factor Human genes 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- WGUYYUOFQYVTLR-BLPRJPCASA-N [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO Chemical compound [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO WGUYYUOFQYVTLR-BLPRJPCASA-N 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 230000003257 anti-anginal effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 210000003709 heart valve Anatomy 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000004862 vasculogenesis Effects 0.000 abstract 1
- 230000000982 vasogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10234192A DE10234192B4 (de) | 2002-07-26 | 2002-07-26 | Verwendung von Erythropoetin |
| PCT/EP2003/008229 WO2004012759A2 (de) | 2002-07-26 | 2003-07-25 | Erythropoetin zur stimulation endothelialer voläuferzellen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IS7633A true IS7633A (is) | 2005-01-06 |
| IS2671B IS2671B (is) | 2010-09-15 |
Family
ID=30128436
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7633A IS2671B (is) | 2002-07-26 | 2005-01-06 | Rauðkornavaki í undirblóðríkisskömmtum |
| IS8817A IS8817A (is) | 2002-07-26 | 2009-05-06 | Rauðkornavaki til örvunar á innanþekju forverafrumum. |
| IS8909A IS8909A (is) | 2002-07-26 | 2010-07-02 | Rauðkornavaki til örvunar á innanþekju forverafrumum. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8817A IS8817A (is) | 2002-07-26 | 2009-05-06 | Rauðkornavaki til örvunar á innanþekju forverafrumum. |
| IS8909A IS8909A (is) | 2002-07-26 | 2010-07-02 | Rauðkornavaki til örvunar á innanþekju forverafrumum. |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7745387B2 (is) |
| EP (3) | EP1779862B1 (is) |
| JP (4) | JP4727988B2 (is) |
| KR (2) | KR20100077033A (is) |
| CN (3) | CN101099731B (is) |
| AT (2) | ATE468132T1 (is) |
| AU (2) | AU2003255290B2 (is) |
| BR (1) | BR0312981A (is) |
| CA (2) | CA2710100A1 (is) |
| CY (2) | CY1108052T1 (is) |
| DE (3) | DE10234192B4 (is) |
| DK (2) | DK1779862T3 (is) |
| EA (3) | EA009463B1 (is) |
| ES (2) | ES2345673T3 (is) |
| HR (3) | HRP20050065A2 (is) |
| IL (2) | IL166401A0 (is) |
| IS (3) | IS2671B (is) |
| MX (1) | MXPA05001120A (is) |
| NO (1) | NO20051002L (is) |
| PL (2) | PL395151A1 (is) |
| PT (2) | PT1526867E (is) |
| SG (1) | SG177004A1 (is) |
| SI (2) | SI1526867T1 (is) |
| UA (2) | UA94913C2 (is) |
| WO (1) | WO2004012759A2 (is) |
| ZA (1) | ZA200500726B (is) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| NZ543612A (en) * | 2003-07-29 | 2008-03-28 | Dompe Spa | Pharmaceutical combination of G-CSF and PLGF useful for blood stem cell |
| DK1699915T3 (da) * | 2003-12-30 | 2010-09-13 | Augustinus Bader | Anvendelse af erythropoietin til levervævsregenerering |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
| AU2005314043A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| PT1973559E (pt) | 2005-11-23 | 2013-02-19 | Acceleron Pharma Inc | Antagonistas de activina-actriia e utilizações para promover o crescimento ósseo |
| MX2008015392A (es) * | 2006-06-07 | 2009-05-05 | Univ Tokushima | Tratamiento de enfermedades isquemicas que usan eritropoyetina. |
| EP2109456A2 (en) * | 2006-09-29 | 2009-10-21 | Centocor Ortho Biotech Inc. | Human epo receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions |
| JP5676849B2 (ja) | 2006-10-20 | 2015-02-25 | 中外製薬株式会社 | 抗ｈｂ−ｅｇｆ抗体を有効成分として含む癌治療剤 |
| CA2666559A1 (en) * | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| US8975374B2 (en) * | 2006-10-20 | 2015-03-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| JP2010515736A (ja) * | 2007-01-10 | 2010-05-13 | エジソン ファーマシューティカルズ， インコーポレイテッド | エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療 |
| TWI548647B (zh) | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| AR065613A1 (es) * | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
| EP2192907B1 (en) * | 2007-08-16 | 2018-04-18 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for therapeutic applications |
| EA201001814A1 (ru) * | 2008-05-22 | 2011-04-29 | Эдисон Фармасьютикалз, Инк. | Лечение митохондриальных заболеваний миметиками эритропоэтина |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN102656187A (zh) | 2009-06-12 | 2012-09-05 | 阿塞勒隆制药公司 | 截短的actriib-fc融合蛋白 |
| BR112012003232B1 (pt) * | 2009-08-13 | 2022-02-22 | Acceleron Pharma Inc | Uso de um polipeptídeo em conjunto com um ativador do receptor de eritropoetina para aumentar os níveis de célula vermelha no sangue ou tratar anemia |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| WO2012003960A1 (en) | 2010-07-06 | 2012-01-12 | Augustinus Bader | Topical application of erythropoietin for the treatment of eye disorders and injuries |
| WO2012148200A2 (ko) * | 2011-04-26 | 2012-11-01 | 아주대학교 산학협력단 | 허혈성 혈관 질환 치료시술 보조용 조성물 |
| WO2015061431A1 (en) * | 2013-10-22 | 2015-04-30 | ConcieValve LLC | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| EP2914277B1 (en) | 2012-11-02 | 2017-09-13 | Celgene Corporation | Activin-actrii antagonists and uses for treating bone and other disorders |
| US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| EP3256585A4 (en) * | 2015-02-13 | 2018-08-15 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
| US11534466B2 (en) * | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| CN116115629A (zh) | 2016-08-17 | 2023-05-16 | 菲克特生物科学股份有限公司 | 核酸产品及其施用方法 |
| CN108114282B (zh) * | 2016-11-28 | 2021-03-02 | 北京大学第三医院 | 他汀类化合物治疗缺血性疾病的用途 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| KR102771895B1 (ko) * | 2017-10-20 | 2025-02-21 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
| RU2678768C1 (ru) * | 2018-09-25 | 2019-02-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте |
| RU2695334C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте |
| JP7501876B2 (ja) | 2019-04-17 | 2024-06-18 | 国立大学法人広島大学 | Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 |
| EP3997059A4 (en) | 2019-07-03 | 2023-12-13 | Factor Bioscience Inc. | CATIONIC LIPIDS AND THEIR USES |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| EP4221736A4 (en) | 2020-10-02 | 2025-03-05 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii variants |
| CN119080909A (zh) * | 2024-08-29 | 2024-12-06 | 深圳赛保尔生物药业有限公司 | 负载peg-epo及间充质干细胞的组合物、药物及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4732889A (en) | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
| ATE79761T1 (de) | 1985-11-27 | 1992-09-15 | Genetics Inst | Behandlung einer krankheit vom aids-typ. |
| US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
| DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| DE3729863A1 (de) | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| JPH03503167A (ja) | 1988-02-24 | 1991-07-18 | アメリカン ナショナル レッド クロス | 部位指定血管形成素子とその使用法 |
| US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| DE4014654A1 (de) | 1990-05-08 | 1991-11-14 | Behringwerke Ag | Galenische waessrige formulierungen von erythropoietin und ihre verwendung |
| DK0575555T3 (da) * | 1991-03-11 | 2001-11-05 | Curis Inc | Proteininduceret morfogenese |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| KR960701650A (ko) | 1993-04-29 | 1996-03-28 | 찰스 엠. 브룩 | 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods) |
| CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| JPH08205860A (ja) * | 1994-01-21 | 1996-08-13 | Usa Government | 造血細胞の膨大化および移植方法 |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| ATE251912T1 (de) | 1994-11-03 | 2003-11-15 | Roche Diagnostics Gmbh | Verwendung des erythropoietins zur behandlung von rheumatoider arthritis |
| US5837675A (en) * | 1995-02-03 | 1998-11-17 | Brox; Alan G. | Synergistic effect of insulin-like growth factor-I and erythropoietin |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| US6274158B1 (en) * | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
| US6284260B1 (en) | 1998-02-04 | 2001-09-04 | Veronica L. Zaharia Czeizler | Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| NZ533098A (en) * | 1999-04-13 | 2006-04-28 | Kenneth S | Modulation of excitable tissue function by peripherally administered erythropoietin at high doses |
| CA2407797A1 (en) | 2000-05-02 | 2001-11-08 | Action Pharma Aps | Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| US7259146B2 (en) * | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US20020065214A1 (en) * | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| KR20040032094A (ko) * | 2001-04-04 | 2004-04-14 | 젠오디세 | 에리트로포이에틴 유전자의 신규한 폴리뉴클레오티드 및폴리펩티드 |
| US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| AU2002357019A1 (en) * | 2001-11-28 | 2003-06-10 | Ortho-Mcneil Pharmaceutical, Inc. | Erythropoietin dosing regimen for treating anemia |
| EP1471930B1 (en) * | 2002-01-09 | 2007-04-11 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
| US6748154B2 (en) * | 2002-03-28 | 2004-06-08 | Nortel Networks Limited | Optical module access tray |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
-
2002
- 2002-07-26 DE DE10234192A patent/DE10234192B4/de not_active Expired - Fee Related
-
2003
- 2003-07-25 CN CN200710127913XA patent/CN101099731B/zh not_active Expired - Fee Related
- 2003-07-25 ES ES07001689T patent/ES2345673T3/es not_active Expired - Lifetime
- 2003-07-25 US US10/522,426 patent/US7745387B2/en not_active Expired - Fee Related
- 2003-07-25 CN CNA038221160A patent/CN1681526A/zh active Pending
- 2003-07-25 UA UAA200801307A patent/UA94913C2/ru unknown
- 2003-07-25 CA CA2710100A patent/CA2710100A1/en not_active Abandoned
- 2003-07-25 KR KR1020107011097A patent/KR20100077033A/ko not_active Ceased
- 2003-07-25 DE DE50312729T patent/DE50312729D1/de not_active Expired - Lifetime
- 2003-07-25 DK DK07001689.4T patent/DK1779862T3/da active
- 2003-07-25 UA UAA200501760A patent/UA85997C2/ru unknown
- 2003-07-25 SG SG2007003890A patent/SG177004A1/en unknown
- 2003-07-25 HR HR20050065A patent/HRP20050065A2/hr not_active Application Discontinuation
- 2003-07-25 EA EA200500281A patent/EA009463B1/ru not_active IP Right Cessation
- 2003-07-25 MX MXPA05001120A patent/MXPA05001120A/es active IP Right Grant
- 2003-07-25 AT AT07001689T patent/ATE468132T1/de not_active IP Right Cessation
- 2003-07-25 EA EA200801236A patent/EA200801236A1/ru unknown
- 2003-07-25 HR HR20070189A patent/HRP20070189A2/xx not_active Application Discontinuation
- 2003-07-25 PT PT03766302T patent/PT1526867E/pt unknown
- 2003-07-25 JP JP2004525322A patent/JP4727988B2/ja not_active Expired - Fee Related
- 2003-07-25 AU AU2003255290A patent/AU2003255290B2/en not_active Ceased
- 2003-07-25 EP EP07001689A patent/EP1779862B1/de not_active Expired - Lifetime
- 2003-07-25 DK DK03766302T patent/DK1526867T3/da active
- 2003-07-25 CA CA002493598A patent/CA2493598A1/en not_active Abandoned
- 2003-07-25 PT PT07001689T patent/PT1779862E/pt unknown
- 2003-07-25 PL PL395151A patent/PL395151A1/pl unknown
- 2003-07-25 HR HR20100187A patent/HRP20100187A2/xx not_active Application Discontinuation
- 2003-07-25 WO PCT/EP2003/008229 patent/WO2004012759A2/de not_active Ceased
- 2003-07-25 CN CN2007101279144A patent/CN101099860B/zh not_active Expired - Fee Related
- 2003-07-25 PL PL03374874A patent/PL374874A1/xx unknown
- 2003-07-25 DE DE50307140T patent/DE50307140D1/de not_active Expired - Lifetime
- 2003-07-25 AT AT03766302T patent/ATE360436T1/de not_active IP Right Cessation
- 2003-07-25 SI SI200330881T patent/SI1526867T1/sl unknown
- 2003-07-25 SI SI200331837T patent/SI1779862T1/sl unknown
- 2003-07-25 ES ES03766302T patent/ES2285195T3/es not_active Expired - Lifetime
- 2003-07-25 EA EA200700196A patent/EA013966B1/ru not_active IP Right Cessation
- 2003-07-25 EP EP10000381A patent/EP2191838A1/de not_active Withdrawn
- 2003-07-25 EP EP03766302A patent/EP1526867B1/de not_active Expired - Lifetime
- 2003-07-25 BR BR0312981-0A patent/BR0312981A/pt not_active IP Right Cessation
- 2003-07-25 KR KR1020057001341A patent/KR20050026513A/ko not_active Ceased
-
2005
- 2005-01-06 IS IS7633A patent/IS2671B/is unknown
- 2005-01-20 IL IL16640105A patent/IL166401A0/xx not_active IP Right Cessation
- 2005-01-25 ZA ZA200500726A patent/ZA200500726B/xx unknown
- 2005-02-24 NO NO20051002A patent/NO20051002L/no not_active Application Discontinuation
-
2007
- 2007-07-02 CY CY20071100871T patent/CY1108052T1/el unknown
-
2009
- 2009-02-25 AU AU2009200748A patent/AU2009200748A1/en not_active Abandoned
- 2009-05-06 IS IS8817A patent/IS8817A/is unknown
-
2010
- 2010-03-18 IL IL204577A patent/IL204577A/en not_active IP Right Cessation
- 2010-04-13 US US12/759,275 patent/US20100247450A1/en not_active Abandoned
- 2010-04-13 US US12/759,321 patent/US20100247452A1/en not_active Abandoned
- 2010-04-13 US US12/759,299 patent/US20100247451A1/en not_active Abandoned
- 2010-07-02 IS IS8909A patent/IS8909A/is unknown
- 2010-07-09 JP JP2010157092A patent/JP2010280670A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157093A patent/JP2010280671A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157094A patent/JP2010280672A/ja not_active Withdrawn
- 2010-07-29 CY CY20101100712T patent/CY1110713T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7633A (is) | Notkun á rauðkornavaka | |
| Mirhoseini et al. | Myocardial revascularization by laser: a clinical report | |
| Yu et al. | Effects of photostimulation on wound healing in diabetic mice | |
| DE3880318D1 (de) | Polypeptide mit kollagen typ iv aktivitaet. | |
| Bhan et al. | Radial artery in CABG: could the early results be comparable to internal mammary artery graft? | |
| DE58905850D1 (de) | Katheter für die perkutane gefäss- und organchirurgie mittels energiestrahlung. | |
| ATE271882T1 (de) | Supplementierte verdichtungsmittel für gewebe, methoden für ihre herstellung und ihre verwendung | |
| Smith et al. | AV anastomosis as a solution for absent venous drainage in replantation surgery | |
| US20080125622A1 (en) | Cardiac wall tension relief with cell loss management | |
| ATE469654T1 (de) | Verwendung des erythropoietins zur regeneration von lebergewebe | |
| Uva et al. | Does bilateral internal thoracic artery grafting increase surgical risk in diabetic patients? | |
| Vicario et al. | Transcoronary sinus delivery of autologous bone marrow and angiogenesis in pig models with myocardial injury | |
| ES2162331T3 (es) | Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea. | |
| NO20021410L (no) | Forebygging og behandling av blodkoagulasjons-relaterte sykdommer | |
| RU92015439A (ru) | Способ лечения рубцовых стенозов гортани | |
| Ko et al. | Durability of prefabricated versus normal random flaps against a bacterial challenge | |
| Yamaguchi et al. | Skin grafting: surgical techniques | |
| Fichter et al. | Present and Future Strategies | |
| Senges et al. | Effect of brief periods of paced ventricular tachycardia on coronary blood flow in dogs before and after graded coronary stenosis | |
| Sanchez | Cultivo in vitro de epidermis. | |
| Howes | The latest wrinkles in wound healing | |
| Okada et al. | Laser Application in the Fields of Cardiovascular Surgery; Experimental and Clinical Studies | |
| WO2004037120A3 (en) | Implantable medical devices using zinc | |
| IL118968A (en) | Apparatus for biostimulation of myocardial tissue by electromagnetic wave radiation |